- Home
- QUIK vs IPHA Comparison
QUIK vs IPHA Comparison
Compare QUIK & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- IPHA
- Stock Information
- Founded
- QUIK 1988
- IPHA 1999
- Country
- QUIK United States
- IPHA France
- Employees
- QUIK N/A
- IPHA N/A
- Industry
- QUIK Semiconductors
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- QUIK Technology
- IPHA Health Care
- Exchange
- QUIK Nasdaq
- IPHA Nasdaq
- Market Cap
- QUIK 145.4M
- IPHA 148.3M
- IPO Year
- QUIK 1997
- IPHA 2019
- Fundamental
- Price
- QUIK $9.14
- IPHA $1.69
- Analyst Decision
- QUIK Strong Buy
- IPHA Strong Buy
- Analyst Count
- QUIK 3
- IPHA 1
- Target Price
- QUIK $11.53
- IPHA $11.50
- AVG Volume (30 Days)
- QUIK 373.7K
- IPHA 49.9K
- Earning Date
- QUIK 02-25-2025
- IPHA 09-12-2024
- Dividend Yield
- QUIK N/A
- IPHA N/A
- EPS Growth
- QUIK N/A
- IPHA N/A
- EPS
- QUIK N/A
- IPHA N/A
- Revenue
- QUIK $21,886,000.00
- IPHA $36,202,722.00
- Revenue This Year
- QUIK N/A
- IPHA N/A
- Revenue Next Year
- QUIK $27.52
- IPHA $101.65
- P/E Ratio
- QUIK N/A
- IPHA N/A
- Revenue Growth
- QUIK 22.93
- IPHA N/A
- 52 Week Low
- QUIK $6.75
- IPHA $1.29
- 52 Week High
- QUIK $20.75
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- QUIK 49.30
- IPHA 42.95
- Support Level
- QUIK $8.37
- IPHA $1.60
- Resistance Level
- QUIK $9.42
- IPHA $1.87
- Average True Range (ATR)
- QUIK 1.17
- IPHA 0.13
- MACD
- QUIK -0.26
- IPHA -0.04
- Stochastic Oscillator
- QUIK 15.43
- IPHA 16.67
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.